Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evelo Biosciences, Inc.EVLO · Entity 108468 | Director | June 08, 2023 | June 12, 2023 |
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Director | June 16, 2026 | June 17, 2026 |
| Lantheus Holdings, Inc.LNTH · Entity 690 | Director | May 14, 2026 | May 18, 2026 |
| TREVENA INCTRVN · Entity 85383 | Director | May 13, 2020 | May 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evelo Biosciences, Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.11 · Expires 2033-06-08 | Direct | 20,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 20,000 · Balance 20,000 F1: The option vests on the earlier of June 8, 2024, and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of June 8, 2024, and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of the grant.
IRONWOOD PHARMACEUTICALS INC
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 250,749 |
Ending reported balance
After 2026-06-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-16 · Grant · Acquired 63,481 · Balance 272,320 F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Row 2 · 2026-06-16 · Sale · Disposed 21,571 · Balance 250,749 F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.66 to $3.78, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.66 to $3.78, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Lantheus Holdings, Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,099 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 4,137 · Balance 30,099 |
TREVENA INC
Report date May 13, 2020 · Filed May 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 · Expires 2030-05-13 | Direct | 64,103 |
Reported balance
After 2020-05-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-13 · Grant · Acquired 64,103 · Balance 64,103 F1: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AERIE PHARMACEUTICALS INC
Report date November 21, 2022 · Filed November 21, 2022
Section 16 reporting ended · disclosed 2022-11-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-21 transaction · row 1
1 source rowRow 1 · 2022-11-21 · Disposition to issuer · Disposed 16,095 · Balance 0 F1: Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.27 · Expires 2030-06-11 | Direct | 0 |
Reported balance
After 2022-11-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-21 · Disposition to issuer · Disposed 7,800 · Balance 0 F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.11 · Expires 2032-06-09 | Direct | 0 |
Reported balance
After 2022-11-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-21 · Disposition to issuer · Disposed 16,854 · Balance 0 F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes.
F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2019 Filed May 16, 2019 21:32 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001209191-19-030525 · doc4.xml · derivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 21:33 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 2,595 | $22.77 | $59,075.18 |
DisclosureSEC source: 0000899243-19-006915 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,510 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.57 to $23.01, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 21:07 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,500 | $14.38 | $21,570.00 |
DisclosureSEC source: 0001209191-19-017305 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,131 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.16 to $14.65, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:16 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 5,353 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005215 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,105 Read SEC document |
| December 06, 2018 Filed Dec 10, 2018 21:56 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,500 | $12.46 | $18,690.00 |
DisclosureSEC source: 0001209191-18-061804 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,631 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 20:01 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,500 | $19.10 | $28,650.00 |
DisclosureSEC source: 0001209191-18-050030 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,131 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.03 to $19.26, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 21:06 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 4,560 | $14.72 | $67,123.20 |
DisclosureSEC source: 0000899243-18-018348 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,752 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.55 to $15.00, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 23:56 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock Option (right to buy) · Derivative | 7,800 | $0.00 Strike: $65.15 | $0.00 |
DisclosureSEC source: 0001209191-18-036807 · doc4.xml · derivative · entry 2 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2028-06-07 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of June 7, 2018. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 23:56 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036807 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on June 7, 2019. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:23 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,500 | $17.62 | $26,430.00 |
DisclosureSEC source: 0001209191-18-036346 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,631 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.41 to $17.87, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 21:29 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 16,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035248 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,131 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document |
| May 16, 2018 Filed May 17, 2018 21:07 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001209191-18-031027 · doc4.xml · derivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 00:15 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,500 | $14.06 | $21,090.00 |
DisclosureSEC source: 0001209191-18-017509 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,908 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.10, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:43 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 7,911 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006657 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,312 Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 21:12 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,500 | $16.45 | $24,675.00 |
DisclosureSEC source: 0001209191-17-064178 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,408 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.18 to $17.03, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 20:38 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,500 | $16.16 | $24,240.00 |
DisclosureSEC source: 0001209191-17-051887 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,908 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.08 to $16.32, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 20:06 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $52.85 | $0.00 |
DisclosureSEC source: 0001209191-17-038854 · doc4.xml · derivative · entry 2 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-08 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of June 8, 2017. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 20:06 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038854 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,850 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on June 8, 2018. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 21:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-037353 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,408 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document |
| May 17, 2017 Filed Jun 6, 2017 20:43 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001209191-17-038139 · doc4.xml · derivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-17 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:07 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 8,730 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005788 · doc4.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,401 Read SEC document |
| January 25, 2017 Filed Jan 26, 2017 23:10 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 2,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-17-000163 · primary_01.xml · nonDerivative · entry 1 McHugh Julie · CIK 0001487179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,671 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.